Here are 6 head-turning deal dispatches from the past week, as covered first on InvestingPro+. 1. Activision Blizzard (NASDAQ:ATVI) stock slipped this week after Politico reported...
Pharmaceutical giant Merck has offered to acquire biopharma firm Imago Biosciences for $1.35 billion.
By Investing.com Staff After surging nearly 16% Tuesday on fresh takeover rumors, Mirati Therapeutics (NASDAQ:MRTX) is adding another 5% Wednesday as Wall Street analysts weigh in...
Rising rates, accelerating inflation, and slowing economy hammered S&P 500 Energy and healthcare shares have been the market’s top gainers Investors should consider...
Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The...
Federal Reserve unlikely to pivot Dow has failed to hold breakouts above 200-day in 2022 Index's impressive rally means bears require confirmation Speculation that the Federal...
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
| Average | 110.41 (+2.71% Upside) |
| High | 125 |
| Low | 100 |
| Price | 107.5 |
| No. of Analysts | 22 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 163.30 | 169.40 | 161.00 | -1.95 | -1.18% | 518.17K | London | |||
| 1,870.00 | 1,882.00 | 1,841.00 | +6.00 | +0.32% | 113.37K | London | |||
| 67.30 | 68.00 | 66.00 | -0.20 | -0.30% | 313.94K | London | |||
| 295.00 | 297.60 | 291.40 | -0.80 | -0.27% | 1.06M | London | |||
| 59.70 | 65.70 | 58.80 | -5.30 | -8.15% | 6.85M | London | |||
| 69.14 | 72.50 | 67.50 | -3.12 | -4.32% | 5.09M | London | |||
| 93.06 | 93.45 | 92.52 | +0.39 | +0.42% | 58.55M | London | |||
| 5.00 | 5.30 | 5.30 | -0.25 | -4.76% | 354.90K | London | |||
| 1,135.00 | 1,154.00 | 1,132.00 | -20.00 | -1.73% | 4.99K | London | |||
| 2,170.00 | 2,170.00 | 2,170.00 | -20.0 | -0.91% | 23.69K | London | |||
| 409.00 | 410.00 | 406.50 | +1.00 | +0.24% | 462.97K | London | |||
| 267.50 | 275.00 | 265.50 | -3.00 | -1.11% | 102.57K | London | |||
| 0.172 | 0.178 | 0.175 | 0.00 | 0.00% | 6.51M | London | |||
| 235.00 | 238.80 | 235.00 | -2.60 | -1.09% | 18.33M | London | |||
| 214.30 | 215.10 | 210.40 | +2.00 | +0.94% | 11.62M | London |